Eloise Hudry, PhD, is an Assistant Professor of Neurology at Harvard Medical School and has been working at the MassGeneral Institute of Neurodegenerative Diseases (MIND) since 2009. She is currently a group leader for a small team of 5 people. MIND was founded with the mission to translate laboratory discoveries into finding new drug candidates to prevent, treat and cure Alzheimer’s, ALS, Huntington’s, Parkinson’s, and other neurodegenerative diseases.

Originally from France, she received a PhD in Neurosciences in Paris (University Rene Descartes Paris 5, Pharmaceutical Science), before coming to the United States for a postdoctoral fellowship at Harvard Medical School. Her PhD work was focused on developing new gene therapy approaches to treat monogenic neurodegenerative diseases such as Adrenoleukodystrophy, Metachromatic dystrophy, etc. She mainly worked on mouse models but her research activity has always been closely connected to the clinical and medical world, and she greatly appreciates the translational aspect of her work.

Eloise joined the laboratory of Professor Bradley Hyman at MGH-Harvard in 2009, primarily working on trying to understand the molecular processes and signaling pathways leading to neurodegeneration in Alzheimer's disease. Her research projects involved skills in molecular biology, biochemistry, surgery, immunohistology, etc.

She is very happy to see her professional career as a researcher being enriched by teaching at MGH Institute for Health Professions. She also participates as a lecturer in the HMS quarter course, "Gene Therapy and Imaging for Nervous System Disorders" every fall.

  • Baccalaureate (with honors), Physics and Chemistry, Lycee Saint-Michel, Annecy, FRANCE
  • BSc (with honors), Cell Biology and Physiology, Ecole normale Superieure, Lyon, FRANCE
  • MSc (with honors), Molecular and Cellular Genetics, Ecole normale Superieure, Lyon, FRANCE
  • PhD (with honors), Neurosciences, University of Rene Descartes, Paris 5, FRANCE

Research Interests

Eloise is especially interested to understand the molecular mechanisms involved in neurodegeneration, with a specific focus on Alzheimer's disease. She also designs novel gene therapy approaches to treat neurological disorders.

Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T, Scheel M, Spires-Jones T, Arbel-Ornath M, Betensky R, Davidson BL, Hyman BT. Gene transfer of human apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med. 2013 Nov 20; 5(212) PubMed

Hori Y, Elmaleh DR, Shoup TM, Takahashi K, Takeda S, Cho H, Irimia D, Hyman BT, and Hudry E. FDA approved asthma therapeutic agent impacts amyloid beta in the brain in a transgenic model of Alzheimer’s disease. J Biol Chem. 2015 Jan 23;290(4):1966-78.

Hudry E, Martin C, Gandhi S, György B, Scheffer DI, Mu D, Merkel SF, Mingozzi F, Fitzpatrick Z, Dimant H, Masek M, Ragan T, Brisson AR, Ramirez SH, Hyman BT, Maguire CA. Exosome-associated AAV vector as a robust and convenient neuroscience tool. 2016. Gene Ther. 2016 Apr;23(4):380-92. PubMed

Arbel-Ornath M*, Hudry E*, Boivin JR, Hashimoto T, Kuchibhotla KV, Hou S, Lattarulo CR, Belcher AM, Shakerdge N, Trujillo PB, Hyman BT and Bacskai BJ. Soluble oligomeric amyloid-β species, in the presence of apolipoprotein E, induce calcium dyshomeostasis in the healthy living mouse brain. *equal contribution between Dr. Arbel-Ornath and Dr. Hudry. Mol Neurodegener. 2017 Mar 21;12(1):27.